5-azactidine and zorubicin for patients with previously treated acute nonlymphocytic leukemia: a Cancer and Leukemia Group B pilot study.

Abstract

Twenty-nine adults with advanced acute nonlymphocytic leukemia were treated with an intensive chemotherapy program consisting of 5-azacitidine and zorubicin. Overall, eight patients (28%) achieved a complete remission. Although only one of 19 patients with refractory leukemia responded, seven of ten patients who were treated immediately following relapse from a prior remission achieved another complete remission. The duration of remission ranged from 5 to 33 weeks (median, 14). Treatment resulted in severe toxic reactions including myelosuppression, renal tubular dysfunction, and elevations in liver enzymes. In addition, each of the 15 patients who died of treatment-associated complications had a severe infection. This combination of 5-azacitidine and zorubicin is relatively ineffective for truly refractory leukemia, but it may be a useful alternative following relapse.

• Authors: B A Peterson, C D Bloomfield, A J Gottlieb, M Coleman, M S Greenberg
• Journal: Cancer treatment reports (Cancer Treat Rep) Vol. 66 Issue 3 Pg. 563-6 (Mar 1982) ISSN: 0361-5960 [Print] United States
• PMID: 6174230 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Azacitidine
• zorubicin
• Daunorubicin

Topics

• Acute Disease
• Adult
• Aged
• Azacitidine (adverse effects, therapeutic use)
• Bone Marrow (drug effects)
• Daunorubicin (adverse effects, analogs & derivatives, therapeutic use)
• Drug Administration Schedule
• Drug Therapy, Combination
• Female
• Humans
• Kidney (drug effects)
• Leukemia (drug therapy)
• Liver (drug effects)
• Male
• Middle Aged
• Pilot Projects